Expansion plans for Australian lice companies

Hatchtech recently announced plans to commercialise its Xeglyze lice treatment product, while Ego Pharmaceuticals expand their international distribution network.

Hatchtech Pty Ltd will be exploring possibilities for commercialisation of XeGlyze Lotion, their head lice treatment product, which is currently undergoing submission to the US Food and Drug Administration (FDA).

XeGlyze acheived successful Phase III Clinical trials last year, and is now at the New Drug Application (NDA) submission stage to the FDA. The NDA is expected to be complete by late 2015, and Hatchtech is now looking to secure a commerical partner for a US market launch.

Ego Pharmaceuticals, the vendor of MOOV head lice treatment products, have announced their expansion into Oman. Almost half of Ego Pharmaceuticals international sales are in the Middle East.